Clinical Trials ArenaOriginal article
MSD’s Phase IIb study of tulisokibart achieves primary endpoint
Phase 2positivetulisokibartPositive
AI Analysis
Summary
MSD's Phase IIb study (MK-7240-012) of tulisokibart achieved its primary endpoint in patients with moderate to severe hidradenitis suppurativa (HS).
Clinical Trial Data
Phase
Phase IIb
Primary Endpoint
Met
Outcome Details
Primary endpoint achieved in Phase IIb study MK-7240-012
Importance:7/10
Sentiment:
0.80
Phase IIbprimary endpoint achievedhidradenitis suppurativa
Read the original article
Published by Clinical Trials Arena on October 1, 2026 8:38 AM